These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 409476)

  • 21. [Efficacy of preventing ischemic heart disease and arterial hypertension at a factory manufacturing computer equipment].
    Mikunis RI; Serkova VK; Monastyrskiĭ IuI
    Ter Arkh; 1987; 59(5):118-22. PubMed ID: 3616929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specialty of principal care physician and Medicare expenditures in patients with coronary artery disease: impact of comorbidity and severity.
    McNamara RL; Powe NR; Thiemann DR; Shaffer T; Weller W; Anderson G
    Am J Manag Care; 2001 Mar; 7(3):261-6. PubMed ID: 11258143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidemiology of coronary disease: a review of the literature].
    Paradis GB; Battista RN; Miranda PS; Spitzer WO; Tremblay J
    Union Med Can; 1985 Mar; 114(3):190-8. PubMed ID: 3890313
    [No Abstract]   [Full Text] [Related]  

  • 24. The epidemiology of coronary heart disease: a review.
    Richard JL
    Eff Health Care; 1985; 2(5):197-209. PubMed ID: 10300103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. U.S. statin guidelines: expensive but not necessarily effective.
    Barry HC; Hoffman JR
    Am Fam Physician; 2007 May; 75(10):1453-4, 1456. PubMed ID: 17555139
    [No Abstract]   [Full Text] [Related]  

  • 26. Coronary risk assessment of university students in Crete with premature parental coronary heart disease.
    Lionis C; Antonopoulou M; Volitaki K; Thireos E
    J Am Coll Health; 2004; 52(5):237-8. PubMed ID: 15029946
    [No Abstract]   [Full Text] [Related]  

  • 27. [10 years of the ischemic heart disease prevention project in northern Karelia].
    Puska P; Tuomilehto J; Salonen JT; Nissinen A
    Cas Lek Cesk; 1985 Mar; 124(13):385-9. PubMed ID: 4005910
    [No Abstract]   [Full Text] [Related]  

  • 28. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
    Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
    CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
    [No Abstract]   [Full Text] [Related]  

  • 29. Geographic variations in coronary heart disease. A perspective on risk factors and prevention.
    Thind IS
    Adv Myocardiol; 1980; 2():527-44. PubMed ID: 6999565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Sneaky disease": the body and health knowledge for people at risk for coronary heart disease in Ontario, Canada.
    Angus J; Evans S; Lapum J; Rukholm E; St Onge R; Nolan R; Michel I
    Soc Sci Med; 2005 May; 60(9):2117-28. PubMed ID: 15743659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential health economic benefits of vitamin supplementation.
    Bendich A; Mallick R; Leader S
    West J Med; 1997 May; 166(5):306-12. PubMed ID: 9217432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Possibilities of primary prevention of ischemic heart disease].
    Oganov RG; Chazova LV
    Gig Sanit; 1992 Apr; (4):39-45. PubMed ID: 1511928
    [No Abstract]   [Full Text] [Related]  

  • 33. [The incidence of risk factors for ischemic heart disease among the men of a nonorganized population].
    Davydova LI; Andreeva ID; Bogriĭ AM; Vodianitskaia NA; Dambrauskas ES
    Vrach Delo; 1988 Nov; (11):35-8. PubMed ID: 3238974
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.
    Montagne O; Vedel I; Durand-Zaleski I
    Clin Ther; 1999 Nov; 21(11):2027-35. PubMed ID: 10890271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential benefits of controlling coronary heart disease risk factors in the United Arab Emirates.
    Abdulle AM; Nagelkerke NJ; Abouchacra S; Obineche EN
    Kidney Blood Press Res; 2008; 31(3):185-8. PubMed ID: 18493155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Practice guidelines for physicians and related economic considerations].
    Simoons ML; Casparie AF
    Ned Tijdschr Geneeskd; 1999 Apr; 143(16):874-5. PubMed ID: 10347660
    [No Abstract]   [Full Text] [Related]  

  • 39. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project.
    Niu S; Zhao D; Zhu J; Liu J; Liu Q; Liu J; Wang W; Smith SC;
    Am Heart J; 2009 Apr; 157(4):709-15.e1. PubMed ID: 19332200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prediction of midlife coronary heart disease and hypertension in young adults: the Johns Hopkins multiple risk equations.
    Pearson TA; LaCroix AZ; Mead LA; Liang KY
    Am J Prev Med; 1990; 6(2 Suppl):23-8. PubMed ID: 2383409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.